IRCCS Mondino MS Centre
The MS Center of the IRCCS National Neurological Insitute Mondino will enrol from sixty to seventy MS patients, eligible according to the defined inclusion and exclusion criteria set for the project. The patients will be enrolled in the study and followed by a multidisciplinary team composed of two senior neurologists, one junior neurologist, one resident neurologist and a neuropsychologist.
Patients involved in the study
The recruitment phase for the BRAINTEASER clinical study has been completed, with 70 MS patients enrolled. The next step is to continue monitoring these participants to collect vital longitudinal data. This ongoing effort will provide valuable insights into disease progression and inform future strategies for managing Multiple Sclerosis effectively.
Key takeaways from the BRAINTEASER observational study
The clinical study has yielded several important lessons. The proposed monitoring devices have demonstrated good feasibility and acceptability, proving to be valuable tools for tracking Multiple Sclerosis. Additionally, the study has reinforced the importance of advising patients to maintain a healthy lifestyle, engage in regular physical activity, and minimise exposure to the pollutants under investigation. These factors are increasingly recognised as having a significant impact on disease progression.
Patient and caregiver perspectives on the BRAINTEASER model
The BRAINTEASER model has been positively received by both patients and their caregivers. Its personalised care approach and improved communication have been particularly appreciated. Moreover, the model has helped some users develop greater awareness of how maintaining a healthy lifestyle and ensuring good air quality can positively influence their disease management.
Future plans for BRAINTEASER
As the BRAINTEASER project concludes, there is a strong commitment to building upon its promising findings. Future efforts will focus on further integrating remote monitoring strategies into everyday clinical practice to enhance patient care and outcomes. These advancements aim to ensure that the benefits of the BRAINTEASER interventions extend beyond the project’s completion, driving lasting improvements in Multiple Sclerosis management.